These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 39012618)

  • 21. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
    Galaverna F; Baccelli F; Zama D; Tridello G; Masetti R; Soncini E; Mura R; Barzaghi F; Colombini A; Prunotto G; D'Amico MR; Calore E; Biffi A; Perruccio K; Gasperini P; Oltolini C; Quagliarella F; Giacomazzi A; Pagliara D; Locatelli F; Cesaro S
    Bone Marrow Transplant; 2024 Apr; 59(4):505-512. PubMed ID: 38272999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
    Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
    Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
    Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
    Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients.
    Groll AH; Schulte JH; Antmen AB; Fraser CJ; Teal VL; Haber B; Caro L; McCrea JB; Fancourt C; Patel M; Menzel K; Badshah C
    Pediatr Infect Dis J; 2024 Mar; 43(3):203-208. PubMed ID: 38241643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
    Derigs P; Radujkovic A; Schubert ML; Schnitzler P; Schöning T; Müller-Tidow C; Hegenbart U; Schönland SO; Luft T; Dreger P; Schmitt M
    Ann Hematol; 2021 Aug; 100(8):2087-2093. PubMed ID: 33270162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation.
    Nakashima T; Inamoto Y; Fukushi Y; Doke Y; Hashimoto H; Fukuda T; Yamaguchi M
    Int J Hematol; 2021 Jun; 113(6):872-876. PubMed ID: 33677768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong.
    Chan TS; Cheng SS; Chen WT; Hsu DC; Chau RW; Kang SH; Alsumali A; Kwong YL
    J Med Econ; 2020 Dec; 23(12):1485-1492. PubMed ID: 33155494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
    Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM
    Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.
    P Daukshus N; Cirincione A; Siver M; Mathew S; Kunvarjee B; Chan A; Boelens JJ; Seo SK; Papanicolaou GA; Kernan NA
    J Pediatric Infect Dis Soc; 2022 Jul; 11(7):337-340. PubMed ID: 35472147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.
    Alsumali A; Chemaly RF; Graham J; Jiang Y; Merchant S; Miles L; Schelfhout J; Yang J; Tang Y
    J Med Virol; 2021 Jun; 93(6):3786-3794. PubMed ID: 32844453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic analysis driven letermovir dosing in pediatric hematopoietic cell transplantation patients with resistant CMV disease.
    Pai VB; Tansmore J; Song E
    Pediatr Transplant; 2024 Feb; 28(1):e14580. PubMed ID: 37466088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
    Kampouri E; Zamora D; Kiem ES; Liu W; Ibrahimi S; Blazevic RL; Lovas EA; Kimball LE; Huang ML; Jerome KR; Ueda Oshima M; Mielcarek M; Zerr DM; Boeckh MJ; Krantz EM; Hill JA
    Clin Microbiol Infect; 2023 Nov; 29(11):1450.e1-1450.e7. PubMed ID: 37532126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
    Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
    Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice.
    Ohmoto A; Fuji S
    Expert Rev Anti Infect Ther; 2024 Apr; 22(4):169-178. PubMed ID: 38404258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
    Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
    Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
    Adedoyin A; Fancourt C; Menzel K; Zhao T; Tomek C; Panebianco D; McCrea JB; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):198-206. PubMed ID: 32700459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
    McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
    Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
    Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
    Royston L; Masouridi-Levrat S; Gotta V; Royston E; Pressacco-Brossier C; Abi Aad Y; Tonoli D; Karmime A; Jayo M; Van Delden C; Lescuyer P; Pfister M; Chalandon Y; Neofytos D
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0065722. PubMed ID: 35876579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.